Alpelisib plus endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study

被引：0
|
作者：
Chia, Stephen
Neven, Patrick
Ciruelos, Eva M.
Lerebours, Florence
Ruiz-Borrego, Manuel
Drullinsky, Pamela
Prat, Aleix
Park, Yeon Hee
Juric, Dejan
Turner, Nicholas C.
Chattar, Yogesh
Patino, Heather
Akdere, Murat
Rugo, Hope S.
机构：
[1] Univ British Columbia, Vancouver, BC, Canada
[2] Univ Hosp, Leuven, Belgium
[3] Hosp 12 Octubre, Med Oncol Dept, Madrid, Spain
[4] PSL Res Univ, Inst Curie, St Cloud, France
[5] Hosp Virgen Rocio Sevilla, Seville, Spain
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
[7] Hosp Clin Barcelona, Barcelona, Spain
[8] Samsung Med Ctr, Seoul, South Korea
[9] Massachusetts Gen Hosp, Boston, MA USA
[10] Royal Marsden NHS Fdn Trust, London, England
[11] Inst Canc Res, London, England
[12] Novartis Healthcare Private Ltd, Hyderabad, India
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] Novartis Pharma AG, Basel, Switzerland
[15] Univ Calif San Francisco, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1078
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Long-Term and Very-Long-Term Disease Control in Patients From BYLieve Study Cohort A With PIK3CA-Mutant, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced Breast Cancer
    Rugo, Hope
    Chia, Stephen K.
    Cortes, Javier
    Curigliano, Giuseppe
    Neven, Patrick
    Dent, Rebecca
    Tolaney, Sara
    Ciruelos, Eva
    Park, Yeon H.
    Roux, Estelle
    Chattar, Yogesh
    Patino, Heather
    Akdere, Murat
    Juric, Dejan
    CANCER RESEARCH, 2023, 83 (05)
  • [32] Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review
    Li, Junjie
    Wang, Zhonghua
    Shao, Zhimin
    CANCER MEDICINE, 2019, 8 (05): : 1943 - 1957
  • [33] Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Shen, Le-Sang
    Jin, Xiao-Yan
    Wang, Xu-Meng
    Tou, Lai-Zhen
    Huang, Jian
    CHINESE MEDICAL JOURNAL, 2020, 133 (09) : 1099 - 1108
  • [34] Efficacy of Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 526 - 534
  • [35] Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Brufsky, Adam M.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2015, 9 : 137 - 147
  • [36] Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) plus fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
    Andre, F.
    Rugo, H. S.
    Juric, D.
    Rubovsky, G.
    Yamashita, T.
    Stemmer, S. M.
    Lu, Y- S.
    Miller, M. K.
    Lorenzo, I.
    Hu, H.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S498 - S499
  • [37] Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
    Inoue, Kenichi
    Masuda, Norikazu
    Iwata, Hiroji
    Takahashi, Masato
    Ito, Yoshinori
    Miyoshi, Yasuo
    Nakayama, Takahiro
    Mukai, Hirofumi
    van der Walt, Jan-Stefan
    Mori, Joji
    Sakaguchi, Sachi
    Kawaguchi, Tsutomu
    Tanizawa, Yoshinori
    Llombart-Cussac, Antonio
    Sledge, George W., Jr.
    Toi, Masakazu
    BREAST CANCER, 2021, 28 (05) : 1038 - 1050
  • [38] Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
    Kenichi Inoue
    Norikazu Masuda
    Hiroji Iwata
    Masato Takahashi
    Yoshinori Ito
    Yasuo Miyoshi
    Takahiro Nakayama
    Hirofumi Mukai
    Jan-Stefan van der Walt
    Joji Mori
    Sachi Sakaguchi
    Tsutomu Kawaguchi
    Yoshinori Tanizawa
    Antonio Llombart-Cussac
    George W. Sledge
    Masakazu Toi
    Breast Cancer, 2021, 28 : 1038 - 1050
  • [39] Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial
    Royce, Melanie
    Bachelot, Thomas
    Villanueva, Cristian
    Ozguroglu, Mustafa
    Azevedo, Sergio J.
    Cruz, Felipe Melo
    Debled, Marc
    Hegg, Roberto
    Toyama, Tatsuya
    Falkson, Carla
    Jeong, Joon
    Srimuninnimit, Vichien
    Gradishar, William J.
    Arce, Christina
    Ridolfi, Antonia
    Lin, Chinjune
    Cardoso, Fatima
    JAMA ONCOLOGY, 2018, 4 (07) : 977 - 984
  • [40] Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial
    Turner, Nick
    Rugo, Hope S.
    Ciruelos, Eva M.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Lerebours, Florence
    Prat, Aleix
    Bachelot, Thomas
    Chia, Stephen
    Balbin, Alejandro
    Joshi, Mukta
    Roux, Estelle
    Arce, Christina H.
    Akdere, Murat
    Juric, Dejan
    CANCER RESEARCH, 2022, 82 (04)
12345